Showing 2771-2780 of 5258 results for "".
- Early Use of CO2 Lasers on Surgical Scars Bests Silicone Gel Treatmenthttps://practicaldermatology.com/news/early-use-of-co2-lasers-on-surgical-scars-bests-silicone-gel-treatment/2458112/Early treatment of surgical scars with a super-pulsed fractional C02 laser shows promise, new research suggests. The study, which appears in Lasers in Surgery and Medicine (LSM), found that laser treatment of
- LEO Pharma Receives EU Marketing Authorization for Kyntheum to Treat Plaque Psoriasishttps://practicaldermatology.com/news/leo-pharma-receives-eu-marketing-authorization-for-kyntheumfor-the-treatment-of-plaque-psoriasis/2458114/The European Commission has granted marketing authorisation for LEO Pharma's Kyntheum (brodalumab), a new biologic for the treatment of moderate-to-severe plaque psoriasis in adults within the European Union who are candidates for systemic therapy. Kyntheum selectively targets the IL-17 recep
- Dr. Jacqualyn Fouse Named Executive Chairman of Dermavanthttps://practicaldermatology.com/news/dr-jacqualyn-fouse-named-executive-chairman-of-dermavent/2458127/Dr. Jacqualyn "Jackie" Fouse is the new Executive Chairman of Dermavant Sciences. Part of the Roivant Sciences family of companies, Dermavant Sciences is developing and, upon regulatory approval, commercializing three investigational d
- Array BioPharma Submits NDAs for Binimetinib and Encorafenib in Advanced Melanomahttps://practicaldermatology.com/news/array-biopharma-submits-ndas-for-binimetinib-and-encorafenib-in-advanced-melanoma/2458131/Array BioPharma submitted two New Drug Applications (NDAs) to the U.S. Food and Drug Administration (FDA) for the use of the combination of binimetinib 45 mg twice daily and encorafenib 450 mg once daily (COMBO450) for the treatment of patients with&nbs
- HydroLotion Scores National Eczema Association Seal of Acceptancehttps://practicaldermatology.com/news/hydrolotion-scores-national-eczema-association-seal-of-acceptance/2458138/Theraplex Company’s HydroLotion Daily Skin Moisturizer now has the National Eczema Association (NEA) Seal of Acceptance. The light-weight moisturizer for the face and body is hypoallergenic, noncomedogenic, and free of fragrances, preservatives
- Study Tallies Adverse Events Reported to FDA for Cosmeticshttps://practicaldermatology.com/news/study-tallies-adverse-events-reported-to-fda-for-cosmetics/2458144/There were 5,144 adverse events reported to the US Food and Drug Administration (FDA) for cosmetics and personal care products from 2004 to 2016, an average of 396 events per year, according to a new research letter published by
- Study Findings Cast Doubt on Link Between Eczema and Cardiovascular Diseasehttps://practicaldermatology.com/news/study-findings-cast-doubt-on-link-between-eczema-and-cardiovascular-disease/2458151/Despite recent findings to the contrary, a new study in the British Journal of Dermatology has found that eczema is likely not associated with an increase in cardiovascular risk factors or diseases. "In our study, people who reported having atopic dermatitis were not at any
- EMA Grants Orphan Status to Tarix's EB Candidiatehttps://practicaldermatology.com/news/ema-grants-orphan-status-to-tarixs-eb-candidiate/2458160/The European Medicines Agency (EMA) granted Orphan Drug status to Tarix Orphan LLC’s lead compound, TXA127, for the treatment of epidermolysis bullosa (EB). TXA127 is a pharmaceutical grade formulation of the naturally occurring peptide
- First Patient Enrolled in DELIVERS Study of Diacerein 1% Ointment for EBShttps://practicaldermatology.com/news/first-patient-enrolled-in-delivers-study-of-diacerein-1-ointment-for-ebs/2458168/The first patient has enrolled in Castle Creek Pharmaceuticals (CCP) Phase 2/3 DELIVERS clinical trial evaluating the safety and efficacy of diacerein 1% ointment (CCP-020) for the treatment of epidermolysis bull
- New Personalized Medicine Approach May Help Treat Even the Most Challenging Woundshttps://practicaldermatology.com/news/new-personalized-medicine-approach-to-wound-healing-may-help-treat-even-the-most-challenging-wounds/2458172/An experimental treatment that allows the reprogramming of blood cells to promote the healing process of cutaneous wound may be beneficial in healing challenging wounds. “We discovered a way to modify specific white blood cells – the macrophages – and make them capable o